These include a four-gene IFN-γ-positive signature, which has been shown to be associated with improved survival in durvalumab-treated patients with mUC [29], with higher expression in PD-L1–positive tumours [30], and high tumour mutational burden, which is associated with better survival outcomes in patients with mUC treated with durvalumab plus tremelimumab [31]. This evidence concerns the gene CD274 and neoplasm.